NPH-301
Cognitive Impairment associated with Schizophrenia
DiscoveryTarget Validation
Key Facts
Indication
Cognitive Impairment associated with Schizophrenia
Phase
Discovery
Status
Target Validation
Company
About Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to addressing the significant unmet medical needs in psychiatry and neurology by advancing a pipeline of innovative CNS therapeutics. Its lead candidate, NPH-101, is a novel rapid-acting antidepressant in Phase 2 development for major depressive disorder. The company's strategy is built on a deep understanding of neurocircuitry and a platform designed to identify compounds with superior efficacy and tolerability compared to existing treatments.
View full company profile